Evidence map›Paper›PMID 39294262›Full record

ArticleNPJ precision oncology2024

Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression.

Miklos Diossy, Viktoria Tisza, Hua Li, Pranshu Sahgal, Jia Zhou, Zsofia Sztupinszki, Denise Young, Darryl Nousome, Claire Kuo, Jiji Jiang and 25 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors.

Miklos Diossy *Danish Cancer Institute, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-0308-6615
Viktoria Tisza *Computational Health Informatics Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Hua Li *Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Pranshu SahgalComputational Health Informatics Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9857-3987
Jia ZhouDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Zsofia SztupinszkiDanish Cancer Institute, Copenhagen, Denmark.
Denise YoungCenter for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Darryl NousomeCenter for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Claire KuoCenter for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Jiji JiangCenter for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Yongmei ChenCenter for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Reinhard EbnerCytoTest Inc., Rockville, MD, USA.
Isabell A SesterhennJoint Pathology Center, Silver Spring, MD, USA.
Joel T MoncurJoint Pathology Center, Silver Spring, MD, USA.
Gregory T ChesnutCenter for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Gyorgy PetrovicsCenter for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Gregory T KlusComputational Health Informatics Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Gabor ValczMTA-SE Molecular Medicine Research Group, Hungarian Academy of Sciences, Budapest, 1051, Hungary.
Pier Vitale NuzzoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5618-8079
Dezso RibliDepartment of Physics of Complex Systems, Eötvös Loránd University, Budapest, Hungary.
Judit BörcsökDanish Cancer Institute, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-3290-3971
Aurel ProszDanish Cancer Institute, Copenhagen, Denmark.
Marcin KrzystanekDanish Cancer Institute, Copenhagen, Denmark.
Thomas RiedGenetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
David SzutsInstitute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.ORCID http://orcid.org/0000-0001-7985-0136
Kinza RizwanDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA.ORCID http://orcid.org/0000-0003-2147-7783
Salma KaocharDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA.
Shailja PathaniaCenter for Personalized Cancer Therapy, University of Massachusetts, Boston, MA, USA.
Alan D D'AndreaDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6168-6294
Istvan CsabaiDepartment of Physics of Complex Systems, Eötvös Loránd University, Budapest, Hungary.ORCID http://orcid.org/0000-0001-9232-9898
Shiv SrivastavaCenter for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Matthew L FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. freedman@broadinstitute.org.ORCID http://orcid.org/0000-0002-0151-1238
Albert DobiCenter for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. adobi@cpdr.org.
Sandor SpisakInstitute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary. Spisak.sandor@ttk.hu.
Zoltan SzallasiDanish Cancer Institute, Copenhagen, Denmark. Zoltan.Szallasi@childrens.harvard.edu.ORCID http://orcid.org/0000-0001-5395-7509

Funding

UMass Boston-DF/HCC U54 Partnership (2 of 2)U54CA156734 · NCI · UNIVERSITY OF MASSACHUSETTS BOSTON · PI Jan Mutchler · 2010 to 2026
$24.9M
The Impact of DNA Damage Repair Abnormalities in Prostate CancerP01CA228696 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI OFFIT, KENNETH, POMERANTZ, MARK M. · 2019 to 2024
$8.7M
Mechanisms Underlying Replication Stress And Genome Instability Upon BRCA2 DeficiencyR01CA273696 · NCI · UNIVERSITY OF MASSACHUSETTS BOSTON · PI PATHANIA, SHAILJA · 2022 to 2025
$1.8M
NCI NIH HHS P01 CA228696NCI NIH HHS R01 CA273696NCI NIH HHS U54 CA156734
6 · The paper itself

Abstract

We analyzed genomic data from the prostate cancer of African- and European American men to identify differences contributing to racial disparity of outcome. We also performed FISH-based studies of Chromodomain helicase DNA-binding protein 1 (CHD1) loss on prostate cancer tissue microarrays. We created CHD1-deficient prostate cancer cell lines for genomic, drug sensitivity and functional homologous recombination (HR) activity analysis. Subclonal deletion of CHD1 was nearly three times as frequent in prostate tumors of African American than in European American men and it associates with rapid disease progression. CHD1 deletion was not associated with HR deficiency associated mutational signatures or HR deficiency as detected by RAD51 foci formation. This was consistent with the moderate increase of olaparib and talazoparib sensitivity with several CHD1 deficient cell lines showing talazoparib sensitivity in the clinically relevant concentration range. CHD1 loss may contribute to worse disease outcome in African American men.

Identifiers

PMID39294262
PMCPMC11411125

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.